Incyte

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Incyte and other ETFs, options, and stocks.

About INCY

Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of proprietary therapeutics. It focuses on hematology and oncology, and inflammation and autoimmunity therapeutic areas.

CEO

William J. Meury

CEOWilliam J. Meury

Employees

2,844

Employees2,844

Headquarters

Wilmington, Delaware

HeadquartersWilmington, Delaware

Founded

1991

Founded1991

Employees

2,844

Employees2,844

INCY Key Statistics

Market cap

20.59B

Market cap20.59B

Price-Earnings ratio

13.89

Price-Earnings ratio13.89

Dividend yield

—

Dividend yield—

Average volume

2.45M

Average volume2.45M

High today

$103.47

High today$103.47

Low today

$99.66

Low today$99.66

Open price

$99.98

Open price$99.98

Volume

928.05K

Volume928.05K

52 Week high

$112.29

52 Week high$112.29

52 Week low

$66.74

52 Week low$66.74

Stock Snapshot

With a market cap of 20.59B, Incyte(INCY) trades at $103.08. The stock has a price-to-earnings ratio of 13.89.

On 2026-06-22, Incyte(INCY) stock moved within a range of $99.66 to $103.47. With shares now at $103.08, the stock is trading +3.4% above its intraday low and -0.4% below the session's peak.

Trading volume for Incyte(INCY) stock has reached 928.05K, versus its average volume of 2.45M.

Over the past 52 weeks, Incyte(INCY) stock has traded between a high of $112.29 and a low of $66.74.

INCY News

TipRanks 1h

Incyte price target raised to $105 from $103 at Truist

Truist raised the firm’s price target on Incyte (INCY) to $105 from $103 and keeps a Hold rating on the shares. The firm updated its model ahead of Q2 earnings...

Investing.com 7h

Incyte settles Medicaid rebate litigation with CMS, expects $246 million benefit - Investing.com

...

TipRanks 8h

Incyte Resolves Opzelura Medicaid Dispute, Gains One-Time Benefit

Unlock powerful investing tools and data-driven insights with TipRanks Premium for more confident investment decisions. Discover top stock picks and new invest...

Analyst ratings

60%

of 30 ratings

Buy

36.7%

Hold

60%

Sell

3.3%

More INCY News

TipRanks 11h

Evan Seigerman Raises Incyte Price Target to $94 but Maintains Hold on Balanced View of Strategic Progress and Post-2029 LOE Risks

In a report released today, Evan Seigerman from BMO Capital upgraded Incyte to a Hold, with a price target of $94.00. Claim 55% Off TipRanks Unlock powerful inv...

TipRanks 3d

Incyte Japan announces approval of Minjuvi combination for DLBCL

Incyte (INCY) Biosciences Japan G.K. announced that Japan’s Ministry of Health, Labour and Welfare has approved Minjuvi in combination with lenalidomide for the...

Simply Wall St 5d

Incyte Stock Could Be 8.1% Undervalued After FDA Priority Review And Trial Results

Recent interest in Incyte (INCY) stock is closely tied to fresh clinical and regulatory milestones, including pivotal data for zilurgisertib in fibrodysplasia o...

Simply Wall St 7d

Will Tafasitamab’s Phase 3 Win and Rare‑Disease Advances Change Incyte's Narrative?

In recent days, Mirum Pharmaceuticals and Incyte reported pivotal data and regulatory progress across several programmes, including positive Phase 3 frontMIND r...

People also own

Based on the portfolios of people who own INCY. This list is generated using Robinhood data, and it’s not a recommendation.

Credo Technology Group

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.